Breakout Session 1: Track A

Rare Disease Alert System (RDAS)

Dr. Qian Zhu
Team Lead, NIH/NCATS



Rare Disease Alert System (RDAS)

Qian Zhu, PhD IFX/DPI/NCATS 1/17/2024



Rare Disease Alert System







Biomedical Resources

Data Collection







Data Annotation











Data Standardization



Data Representation





RDAS Alert







Data Consumption



RDAS STRIDES Network Infrastructure




RDAS UI - https://rdas.ncats.nih.gov/





RDAS UI – Disease page



American journal

Kantarjian H, Jab Department of Le Houston, Texas, L

STUDIES ON THE DEVELOPM

Abstract

We wish to test the hypothe the bone marrow. This idea for it in previous studies of lymphomas arise in the lym centers. In the present stud hybridization techniques wi determinants expressed by Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

(Study Type

Interventional

Status

Completed

Phase

Phase 2

Summary

Epidemiologies

Epidemiolog incidence Epidemiolog 1-2 cases pe Location:

Funding Agency

National Cancer Institute

Funding

Total Cost

\$179,272.00

To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.

Study Diseases

Conditions (2)

Locations (7)

Sub Projects: 3

1987 STUDIES C

Substances

Show Abstract

Imatinib Mesylate

Other Diseases

Chronic myeloi

Diseases Stu

Lymphoma

Design 1

Primary Purpose

Study Design

Participant Info

Treatment

Detailed Description

Combined modelity thereny may

First Posted

NCT00000801


Unknown

Last Update


November 1, 2012

Sponsor >


RDAS neo4j - https://rdas.ncats.nih.gov/browser




RD based publication landscape analysis



RD based funding landscape analysis







RD based CT landscape analysis

Number of clinical trials by intervention types

Intervention Type	# CT
Drug	123,863
Other	32,421
Device	15,273
Procedure	19,143
Biological	18,077
Behavioral	9,297
Diagnostic Test	5,549
Radiation	4,520
Dietary Supplement	4,176
Genetic	1,945
Combination Product	838

Top 10 rare diseases with the greatest number of clinical trials

GARD ID	GARD Name	# CT
GARD:0020511	Rare carcinoma of pancreas	4069
GARD:0021758	Hereditary gastric cancer	3412
GARD:0006383	Carcinoma of esophagus	3222
GARD:0007108	Multiple myeloma	2718
GARD:0020548	Lymphoma	2594
	Malignant lymphoma with peripheral	
GARD:0020387	neuropathy	2592
GARD:0021062	Primary oculocerebral lymphoma	2592
GARD:0021064	Primary organ-specific lymphoma	2592
GARD:0020110	Malignant melanoma of the mucosa	2320
GARD:0012772	Rare malignant breast tumor	2294



Acknowledgement

IFX/DPI/NCATS



Timothy Sheils



Sungrim Moon



Ewy A. Mathé

Previous IFX trainees





William Kariampuzha Jeremy Parker Yang



Jennifer John

ITRB/NCATS



Devon Leadman Jaber Valinejad



Carlin Biyoo



Hugo Hernandez



Mariam Deacy



Sam Michael

DRDRI/NCATS



Yanji Xu

This research was supported in part by the Intramural and Extramural program of the NCATS/NIH, and High Value Dataset program (HVD) from ODSS/NIH